Oncology Views & Analysis | pharmaphorum

Skip to main content

Wednesday 1 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Views & Analysis

Oncology

ASCO 2025 interview with Annemarie Hanekamp

BioNTech’s ASCO 2025 oncology advances: New data on bispecif...

At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.

Oncology

ASCO 2025 interview with Daejin Abidoye

AbbVie’s ASCO 2025 ADC breakthroughs: Transforming oncology ...

Oncology

Tim Lewis, Vanitha Sankaran, Sarah Henry, Jordan Schell - with pharmaphorum

ASCO 2025 insights: EVERSANA experts on AI, biomarkers, and ...

Oncology

lady walking and listening to audio

Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat...

At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.

Oncology

ASCO 2025 interview with Dr Jason Westin

Breaking barriers to CAR T-cell therapy: The vision for expa...

Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.

Oncology

lady listening to audio on tablet device

Live from ASCO 2025: Boehringer Ingelheim on unmet needs and...

Load more results

Editor's Picks

Novartis snaps up PI3Kα breast cancer drug in $3bn deal

US court says pharma giants must face False Claims suit

Meningitis outbreak in UK prompts call to widen vaccination

US judge rules Kennedy's vaccine changes 'unlawful'

Generic semaglutide in India, and other weight-loss news

News

Lilly bags FDA okay for Wegovy pill rival orforglipron

Lilly bags FDA okay for Wegovy pill rival orforglipron

Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company